Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

<p>Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of new preclinical data demonstrating that […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/preclinical-data-demonstrate-anti-siglec-15-treatment-reduced-bone-loss-and-enhanced-bone-quality-in-mice-with-moderate-to-severe-osteogenesis-imperfecta-oi/">Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>